This is an interventional, modular, open-label, multicenter study to primarily evaluate the safety and tolerability of AZD0120 in adult participants with multiple myeloma (MM).
Males and females ≥18 years of age at the time of consent
Participant must have documented diagnosis of MM per IMWG diagnostic criteria
ECOG performance status of 0 or 1.
Adequate organ and bone marrow function.
Have received prior treatment with CAR T therapy directed at any target
Known active, or prior history of central nervous system (CNS) involvement or exhibits clinical signs of meningeal involvement of multiple myeloma
Active or history of plasma cell leukemia at the time of screening
Seropositive for human immunodeficiency virus (HIV)
AstraZeneca
Lead sponsor